Transient impact of lenacapavir against MDR HIV-2 without other active ART
1 January 2025. Related: Antiretrovirals, Treatment strategies, Virology, Drug resistance.
2025
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
1 January 2025. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.